Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ajona, Daniel ^a   Razquin, Cristina ^a   Pastor, Maria Dolores ^b   Pajares, Maria Jose ^a,c   Garcia, Javier ^d   Cardenal, Felipe ^e   Fleischhacker, Michael ^f   Lozano, Maria Dolores ^d   Zulueta, Javier J ^d   Schmidt, Bernd ^f   Nadal, Ernest ^e   Paz Ares, Luis ^b   Montuenga, Luis M ^a,c   Pio, Ruben ^a,g  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; CYTOKERATIN 19 FRAGMENT; ANTIGEN CYFRA21.1; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; CYTOKERATIN 19; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ADULT; ARTICLE; BRONCHOSCOPY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPUTUM; ADENOCARCINOMA; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; COMPLEMENT ACTIVATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT C4B; COMPLEMENT C5A; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; ROC CURVE; SMALL CELL LUNG CARCINOMA; SPUTUM;

EID: 84925813755     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119878     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63: 11-30. doi: 10.3322/caac.21166 PMID: 23335087
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. (2012) Cancer treatment and survivorship statistics. CA Cancer J Clin 62: 220-41. doi: 10.3322/caac.21149 PMID: 22700443
3. Mazzone P, Jain P, Arroliga AC, Matthay RA (2002) Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med 23: 137-58, ix. PMID: 11901908
4. Postmus PE (2005) Bronchoscopy for lung cancer. Chest 128: 16-8. PMID: 16002910
5. Schreiber G, McCrory DC (2003) Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 123: 115S-128S. PMID: 12527571
6. Sen S, Reddy VG, Khanna N, Guleria R, Kapila K, Singh N (2001) A comparative study of telomerase activity in sputum, bronchial washing and biopsy specimens of lung cancer. Lung Cancer 33: 41-9. PMID: 11429194
7. Hong YJ, Hur J, Lee HJ, Nam JE, Kim YJ, Kim HS, et al. (2011) Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer. J Thorac Oncol 6: 1330-5. doi: 10.1097/JTO.0b013e31822462b1 PMID: 21847061
8. Li QK, Shah P, Li Y, Aiyetan PO, Chen J, Yung R, et al. (2013) Glycoproteomic Analysis of Bronchoalveolar Lavage (BAL) Fluid Identifies Tumor-Associated Glycoproteins from Lung Adenocarcinoma. J Proteome Res 12: 3689-96. doi: 10.1021/pr400274w PMID: 23802180
9. Li J, Chen P, Li XQ, Bao QL, Dai CH, Ge LP (2012) Elevated levels of survivin and livin mRNA in bronchial aspirates as markers to support the diagnosis of lung cancer. Int J Cancer 132: 1098-104. doi: 10.1002/ijc.27757 PMID: 22930255
10. Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, et al. (2004) Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 22: 2363-70. PMID: 15197197
11. Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Ratovitski E, Sidranski D, et al. (2004) Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10: 2284-8. PMID: 15073103
12. Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A, Schlegel T, et al. (2012) Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 40: 825-32. doi: 10.3892/ijo.2011.1264 PMID: 22108652
13. Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, et al. (2013) Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. J Natl Cancer Inst 105(18):1385-93. doi: 10.1093/jnci/djt205 PMID: 23940286
14. Hur J, Lee HJ, Nam JE, Kim YJ, Hong YJ, Kim HY, et al. (2012) Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. BMC Cancer 12: 392. doi: 10.1186/1471-2407-12-392 PMID: 22954172
15. Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, et al. (2010) Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. Cancer Epidemiol Biomarkers Prev 19: 2665-72. doi: 10.1158/1055-9965.EPI-10-0467 PMID: 20802023
16. Gal P, Ambrus G, Zavodszky P (2002) C1s, the protease messenger of C1. Structure, function and physiological significance. Immunobiology 205: 383-94. PMID: 12396001
17. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. (2012) Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 189: 4674-83. doi: 10.4049/jimmunol.1201654 PMID: 23028051
18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
19. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-7. PMID: 9187198
20. Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3: 319-28. PMID: 12639809
21. Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13: e178-85. doi: 10.1016/S1470-2045(11)70335-7 PMID: 22469128
22. Finn OJ (2005) Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 353: 1288-90. PMID: 16177255
23. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T (1998) Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113: 173-82. PMID: 9717965
24. Ajona D, Castano Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, et al. (2004) Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64: 6310-8. PMID: 15342420
25. Varsano S, Frolkis I, Ophir D (1995) Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am J Respir Crit Care Med 152: 1087-93. PMID: 7545058
26. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178: 5991-8. PMID: 17442984
27. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45: 169-79. PMID: 17548110
28. Goebell PJ, Groshen SL, Schmitz-Drager BJ (2008) Guidelines for development of diagnostic markers in bladder cancer. World J Urol 26: 5-11. doi: 10.1007/s00345-008-0240-9 PMID: 18253738
29. Luna Coronell JA, Syed P, Sergelen K, Gyurjan I, Weinhausel A (2012) The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics. J Proteomics 76 Spec No.: 102-15. doi: 10.1016/j.jprot.2012.07.022 PMID: 22842156
30. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-84. PMID: 16395409
31. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, et al. (2013) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Cancer Epidemiol Biomarkers Prev 22: 2161-81. doi: 10.1158/1055-9965.EPI-13-0621 PMID: 24057574
32. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108: 3713-8. doi: 10.1073/pnas.1100048108 PMID: 21300873
33. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, et al. (2013) A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 5: 207ra142.
34. Cooper KM, Moore M, Hilton AM (1981) C1q binding activity in the sera of patients with chronic lung diseases. Clin Exp Immunol 45: 18-28. PMID: 6975678
35. Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7: 649-54. doi: 10.1097/JTO.0b013e31824a8db0 PMID: 22425913